Pharmos gets $1.3m chief scientist grant

About 50% of the funding is allocated for research and development expenditures within Israel and 50% is allocated for international expenditures for the fiscal 2006.

By SHARON WROBEL
April 11, 2006 08:09

Rehovot-based therapeutics company Pharmos has received a $1.3 million grant from the Office of the Chief Scientist for the development of the company's drug treatment for moderate-to-severe pain indications, the CB2-selective platform of synthetic cannabinoids. About 50 percent of the funding is allocated for research and development expenditures within Israel and 50% is allocated for international expenditures for the fiscal 2006. A portion of the grant will be applied to late-stage preclinical and clinical costs for developing cannabinor, the company's lead CB2-selective drug candidate for the treatment of pain.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Cookie Settings